Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCDANASDAQ:CYCNNASDAQ:GRINASDAQ:NERV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCDABioCardia$2.18+2.1%$2.22$1.63▼$5.04$11.26M0.82289,212 shs11,824 shsCYCNCyclerion Therapeutics$3.19+0.6%$2.95$1.27▼$9.47$10.24M1.671.11 million shs14,019 shsGRIGRI Bio$1.42-1.0%$1.52$1.10▼$64.09$3.03M-1.68298,346 shs26,738 shsNERVMinerva Neurosciences$1.85+3.1%$1.57$1.15▼$3.69$12.87M-0.3725,166 shs6,662 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCDABioCardia-1.84%-1.39%-12.35%-18.70%-51.92%CYCNCyclerion Therapeutics+1.28%+11.23%+4.59%+13.21%+14.44%GRIGRI Bio-1.38%+4.38%-25.13%-78.20%-97.75%NERVMinerva Neurosciences-2.43%+20.33%+12.11%+10.06%-43.24%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCDABioCardia3.4716 of 5 stars3.85.00.00.02.22.50.6CYCNCyclerion Therapeutics1.4011 of 5 stars0.05.00.00.00.63.30.6GRIGRI Bio2.5852 of 5 stars3.55.00.00.00.90.01.3NERVMinerva Neurosciences1.9005 of 5 stars3.03.00.04.60.00.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCDABioCardia 3.50Strong Buy$25.001,049.43% UpsideCYCNCyclerion Therapeutics 0.00N/AN/AN/AGRIGRI Bio 3.00Buy$22.001,454.77% UpsideNERVMinerva Neurosciences 2.00Hold$5.00171.00% UpsideCurrent Analyst Ratings BreakdownLatest GRI, NERV, BCDA, and CYCN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025GRIGRI BioAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $34.004/14/2025GRIGRI BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 6/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCDABioCardia$3K3,754.05N/AN/A($1.11) per share-1.96CYCNCyclerion Therapeutics$2.08M4.92N/AN/A$4.62 per share0.69GRIGRI BioN/AN/AN/AN/A$5.22 per shareN/ANERVMinerva NeurosciencesN/AN/AN/AN/A($4.07) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCDABioCardia-$11.57M-$2.33N/AN/AN/A-1,999.77%N/A-208.38%8/12/2025 (Estimated)CYCNCyclerion Therapeutics-$5.26M-$1.16N/A∞N/AN/A-55.32%-48.35%8/5/2025 (Estimated)GRIGRI Bio-$13.04M-$11.56N/AN/AN/AN/A-289.05%-165.01%8/12/2025 (Estimated)NERVMinerva Neurosciences-$30M$0.82N/AN/AN/AN/AN/A-6.74%8/5/2025 (Estimated)Latest GRI, NERV, BCDA, and CYCN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025GRIGRI Bio-$4.08-$5.80-$1.72-$5.80N/AN/A5/14/2025Q1 2025BCDABioCardia-$0.39-$0.59-$0.20-$0.59N/AN/A5/13/2025Q1 2025NERVMinerva Neurosciences-$1.07-$0.50+$0.57-$0.50N/AN/A3/26/2025Q4 2024BCDABioCardia-$0.87-$0.25+$0.62-$0.25$0.02 million$0.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCDABioCardiaN/AN/AN/AN/AN/ACYCNCyclerion TherapeuticsN/AN/AN/AN/AN/AGRIGRI Bio$1.91134.98%N/AN/A N/ANERVMinerva NeurosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCDABioCardiaN/A1.781.78CYCNCyclerion TherapeuticsN/A5.075.07GRIGRI BioN/A3.103.10NERVMinerva NeurosciencesN/A6.236.23Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCDABioCardia20.57%CYCNCyclerion Therapeutics75.62%GRIGRI Bio33.95%NERVMinerva Neurosciences34.56%Insider OwnershipCompanyInsider OwnershipBCDABioCardia20.00%CYCNCyclerion Therapeutics34.30%GRIGRI Bio0.13%NERVMinerva Neurosciences8.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCDABioCardia405.18 million3.67 millionOptionableCYCNCyclerion Therapeutics303.21 million1.73 millionNo DataGRIGRI Bio12.14 million8.92 millionNot OptionableNERVMinerva Neurosciences96.99 million6.39 millionNot OptionableGRI, NERV, BCDA, and CYCN HeadlinesRecent News About These CompaniesMinerva Neurosciences, Inc: Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business UpdatesMay 14, 2025 | finanznachrichten.deMinerva Neurosciences Reports First Quarter 2025 Financial Results and Business UpdatesMay 13, 2025 | globenewswire.comMinerva Neurosciences Inc.April 23, 2025 | barrons.comMinerva Neurosciences regains Nasdaq complianceMarch 21, 2025 | investing.comMinerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Business UpdatesFebruary 25, 2025 | globenewswire.comMinerva Neurosciences stock hits 52-week low at $2.02February 12, 2025 | msn.comMinerva Neurosciences Stock Hits 52-Week Low at $2.03January 22, 2025 | msn.comMinerva Neurosciences Reports Third Quarter 2024 Financial Results and Business UpdatesNovember 6, 2024 | markets.businessinsider.comMinerva Neurosciences Reports Third Quarter 2024 Financial Results and Business UpdatesNovember 5, 2024 | globenewswire.com'It has meant everything': Minerva girls win second straight cross country state titleNovember 4, 2024 | msn.comMinerva Fabienne Hase and Nikita Volodin of Germany sit in top spot after pairs shortNovember 2, 2024 | msn.comUS to Overtake China as Top Beef Importer From Brazil’s MinervaNovember 1, 2024 | bloomberg.comCommunity Conversations: El Paso Sheriff candidate Minerva Torres SheltonOctober 30, 2024 | msn.comNeuroscientist, Musician, and Author Dr. Daniel Levitin Talks New Book ‘I Heard There Was a Secret Chord: Music as Medicine’ and More (INTERVIEW)October 28, 2024 | glidemagazine.comPotential ingredient to prevent hyperpigmentation after being treated for varicose veinsOctober 28, 2024 | labroots.comMinerva chamber member honored as 'Bright Star'October 28, 2024 | yahoo.comHigh school cross country: Minerva sweeps boys and girls district titles againOctober 21, 2024 | msn.comCross country or soccer? Minerva's Tateum Richard decided on both and she excels in eachOctober 19, 2024 | cantonrep.comHow sweep it is: Minerva cross country teams earn EBC boys and girls team titlesOctober 14, 2024 | msn.comMusic, games set Friday for Minerva Nights on North MarketOctober 14, 2024 | yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s Watching3 Quality Stocks Trading Near 52-Week LowsBy Gabriel Osorio-Mazilli | May 30, 2025View 3 Quality Stocks Trading Near 52-Week LowsCAVA's Explosive Growth Makes It a Must-Watch StockBy Gabriel Osorio-Mazilli | May 19, 2025View CAVA's Explosive Growth Makes It a Must-Watch StockGRI, NERV, BCDA, and CYCN Company DescriptionsBioCardia NASDAQ:BCDA$2.17 +0.05 (+2.11%) As of 02:43 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.Cyclerion Therapeutics NASDAQ:CYCN$3.19 +0.02 (+0.63%) As of 03:03 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.GRI Bio NASDAQ:GRI$1.42 -0.02 (-1.05%) As of 02:02 PM EasternGRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.Minerva Neurosciences NASDAQ:NERV$1.84 +0.06 (+3.07%) As of 03:05 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Slides on Solid Earnings, AI Outlook Still Strong The Market’s Silent Warning: What Bonds and Gold Reveal MongoDB Affirms Outlook and Accelerates Stock Price Reversal Are NVIDIA's Ethernet Wins Signs of Hope or Horror for Arista? AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? Why Visa's Innovation Engine Keeps It a Top Portfolio Pick Is Meta Plotting a Stablecoin Comeback Years After Libra's Flop? NVIDIA Regains Top Spot; FOMO Is Why It Will Continue to Rise Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
